Long Grove partners with Sunny Pharmtech to launch cyclophosphamide for injection
Long Grove Pharmaceuticals is expanding its product offerings through a strategic in-licensing of cyclophosphamide for injection.
Cyclophosphamide for injection will be manufactured by Sunny Pharmtech in Taiwan.
Cyclophosphamide for injection is an antineoplastic chemotherapy medication that slows the growth of cancer cells. It is used to treat multiple malignant diseases, including blood cancers and solid tumors.
Sunny Pharmtech received Food and Drug Administration approval for the drug in October 2023. It's currently available in 500 milligram, 1 gram and 2 gram dry powder vials.
[Read more: Long Grove to market norepinephrine in sodium chloride premix injection]
“Our team at Long Grove Pharmaceuticals has a long history of collaboration with Sunny Pharmtech,” said Peter Karas, chief commercial officer at Long Grove Pharmaceuticals. “This current opportunity to jointly offer cyclophosphamide continues our commitment to improving customer choice by increasing access to generics.”
“Our partnership with Long Grove Pharmaceuticals helps ensure we can successfully bring cyclophosphamide to market in the U.S.,” said Yon-Lian Wu, founder, chairman and CEO at Sunny Pharmtech. “We’re excited about the launch of cyclophosphamide, but also by the continued opportunity to collaborate on pharmaceutical products that save and improve lives.”
[Read more: Long Grove intros single-pack for generic Hemabate]